Arcutis Biotherapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 6, 2025 and accepted by EDGAR at Aug 6, 2025, 16:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $81.5m | us-gaap:Revenues |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $147.3m | us-gaap:Revenues |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $7.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $16.3m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $19.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $37.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $69.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-30 | $133.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$14.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$39.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $3.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $6.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-04-01 to 2025-06-30 | $342.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | $621.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$15.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$40.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 126,997,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 126,519,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$30.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $686.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-06-30 | $72.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $332.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $352.4m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $103.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $213.5m | us-gaap:Liabilities |
| Long-term debt | At period end2025-06-30 | $107.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-06-30 | $1.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-06-30 | $139.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001787306-25-000124. Last ingested by Listed: Nov 4, 2026, 20:19 ET. Listed shows no prices and gives no investment advice.